The Influence of the Combined Treatment With Vadimezan (ASA404) and Taxol on the Growth of U251 Glioblastoma Xenografts

BMC Cancer - United Kingdom
doi 10.1186/1471-2407-12-242
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Temporal Aspects of the Action of ASA404 (Vadimezan; DMXAA)

Expert Opinion on Investigational Drugs
MedicinePharmacology
2010English

NT113, a Pan-Erbb Inhibitor With High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts With EGFR Amplification

Molecular Cancer Therapeutics
Cancer ResearchOncology
2014English

Low Concentration of Quercetin Antagonizes the Invasion and Angiogenesis of Human Glioblastoma U251 Cells

OncoTargets and Therapy
OncologyPharmacology
2017English

Combined Inhibitory Effects of Celecoxib and Fluvastatin on the Growth of Human Hepatocellular Carcinoma Xenografts in Nude Mice

Journal of International Medical Research
BiochemistryMedicineCell Biology
2010English

The Influence of Endothelial Hyperplasia on Pseudoprogression Development in Patients With Glioblastoma

Srpski Arhiv Za Celokupno Lekarstvo
Medicine
2019English

Design and Synthesis of Simplified Taxol Analogs Based on the T-Taxol Bioactive Conformation

Bioorganic and Medicinal Chemistry
Organic ChemistryMolecular MedicineMolecular BiologyBiochemistryClinical BiochemistryPharmaceutical ScienceDrug Discovery
2011English

Accumulation of Low‑dose BIX01294 Promotes Metastatic Potential of U251 Glioblastoma Cells

Oncology Letters
Cancer ResearchOncology
2017English

The Role of Intravitreal Chemotherapy With Melfalan in the Combined Treatment of Retinoblastoma With Endophitic Character of Growth

Effective Pharmacotherapy
2019English

Comprehensive Genomic Profiling of Glioblastoma Tumors, BTICs, and Xenografts Reveals Stability and Adaptation to Growth Environments

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy